Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Adeno-associated virus in the liver: natural history and consequences in tumour development.

La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, Guettier C, Paradis V, Amaddeo G, Laurent A, Possenti L, Chiche L, Bioulac-Sage P, Blanc JF, Letouze E, Nault JC, Zucman-Rossi J.

Gut. 2019 Aug 2. pii: gutjnl-2019-318281. doi: 10.1136/gutjnl-2019-318281. [Epub ahead of print]

PMID:
31375600
2.

High Impact: The Role of Promiscuous Binding Sites in Polypharmacology.

Cerisier N, Petitjean M, Regad L, Bayard Q, Réau M, Badel A, Camproux AC.

Molecules. 2019 Jul 10;24(14). pii: E2529. doi: 10.3390/molecules24142529.

3.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811. [Epub ahead of print]

PMID:
31206197
4.

RSPO2 abnormal transcripts result from read-through in liver tumours with high ß-catenin activation and CTNNB1 mutations.

Bayard Q, Nault JC, Zucman-Rossi J.

Gut. 2019 Jun 1. pii: gutjnl-2019-319089. doi: 10.1136/gutjnl-2019-319089. [Epub ahead of print] No abstract available.

PMID:
31154392
5.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S.

Gastroenterology. 2019 Sep;157(3):760-776. doi: 10.1053/j.gastro.2019.05.001. Epub 2019 May 4.

PMID:
31063779
6.

A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Hepatology. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.

PMID:
30908678
7.

Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.

Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E.

Nat Commun. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.

8.

Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma.

Calderaro J, Letouzé E, Bayard Q, Boulai A, Renault V, Deleuze JF, Bestard O, Franco D, Zafrani ES, Nault JC, Moutschen M, Zucman-Rossi J.

N Engl J Med. 2018 Sep 20;379(12):1178-1180. doi: 10.1056/NEJMc1805673. No abstract available.

PMID:
30231230
9.

Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer.

Shinde J, Bayard Q, Imbeaud S, Hirsch TZ, Liu F, Renault V, Zucman-Rossi J, Letouzé E.

Bioinformatics. 2018 Oct 1;34(19):3380-3381. doi: 10.1093/bioinformatics/bty388.

PMID:
29771315
10.

Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.

Letouzé E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J.

Nat Commun. 2017 Nov 3;8(1):1315. doi: 10.1038/s41467-017-01358-x.

Supplemental Content

Loading ...
Support Center